Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria

Kyung Yeol Lee, Dong Heon Kim, Tae Jin Kang, Ju Kim, Gook Hyun Chung, Han Sang Yoo, Charles J. Arntzen, Moon Sik Yang, Yong Suk Jang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia. Among the virulence factors, ApxIIA, a bacterial exotoxin, is reportedly expressed in many serotypes and is considered as a candidate for the development of a vaccine against the bacterial infection. Previously, we isolated a field strain of A. pleuropneumoniae serotype 2 in Korea and characterized its exotoxins to develop an oral vaccine. In this study, we initially confirmed the immunogenicity of ApxIIA expressed in Escherichia coli. We then developed transgenic tobacco expressing ApxIIA and tested its efficacy to induce a protective immune response against A. pleuropneumoniae infection after oral administration of the plant powder. We observed that protective immune responses were induced in mice after oral administration of the plant powder once a week for 4 weeks. Immunoassays revealed that the levels of antigen-specific immunoglobulin G against ApxIIA increased in mice that were fed a powder made from the transgenic plant, but not in mice fed a powder made from wild-type tobacco. Additionally, mice fed the transgenic plant powder were protected from an injection of a lethal dose of A. pleuropneumoniae. These results support that the transgenic plant may be a suitable candidate for an oral vaccine that could be used effectively against A. pleuropneumoniae infection.

Original languageEnglish (US)
Pages (from-to)381-389
Number of pages9
JournalFEMS Immunology and Medical Microbiology
Volume48
Issue number3
DOIs
StatePublished - Dec 2006

Fingerprint

Actinobacillus pleuropneumoniae
Genetically Modified Plants
Powders
Tobacco
Oral Administration
Actinobacillus Infections
Exotoxins
Vaccines
Pleuropneumonia
Capital Punishment
Virulence Factors
Korea
Immunoassay
Bacterial Infections
Swine
Immunoglobulin G
Bacteria ApxII toxin
Escherichia coli
Antigens

Keywords

  • Actinobacillus pleuropneumoniae
  • Edible vaccine
  • Transgenic plant

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Infectious Diseases

Cite this

Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. / Lee, Kyung Yeol; Kim, Dong Heon; Kang, Tae Jin; Kim, Ju; Chung, Gook Hyun; Yoo, Han Sang; Arntzen, Charles J.; Yang, Moon Sik; Jang, Yong Suk.

In: FEMS Immunology and Medical Microbiology, Vol. 48, No. 3, 12.2006, p. 381-389.

Research output: Contribution to journalArticle

Lee, Kyung Yeol ; Kim, Dong Heon ; Kang, Tae Jin ; Kim, Ju ; Chung, Gook Hyun ; Yoo, Han Sang ; Arntzen, Charles J. ; Yang, Moon Sik ; Jang, Yong Suk. / Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. In: FEMS Immunology and Medical Microbiology. 2006 ; Vol. 48, No. 3. pp. 381-389.
@article{8c4f9887f5334c3a8d683e4734cd6bb5,
title = "Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria",
abstract = "Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia. Among the virulence factors, ApxIIA, a bacterial exotoxin, is reportedly expressed in many serotypes and is considered as a candidate for the development of a vaccine against the bacterial infection. Previously, we isolated a field strain of A. pleuropneumoniae serotype 2 in Korea and characterized its exotoxins to develop an oral vaccine. In this study, we initially confirmed the immunogenicity of ApxIIA expressed in Escherichia coli. We then developed transgenic tobacco expressing ApxIIA and tested its efficacy to induce a protective immune response against A. pleuropneumoniae infection after oral administration of the plant powder. We observed that protective immune responses were induced in mice after oral administration of the plant powder once a week for 4 weeks. Immunoassays revealed that the levels of antigen-specific immunoglobulin G against ApxIIA increased in mice that were fed a powder made from the transgenic plant, but not in mice fed a powder made from wild-type tobacco. Additionally, mice fed the transgenic plant powder were protected from an injection of a lethal dose of A. pleuropneumoniae. These results support that the transgenic plant may be a suitable candidate for an oral vaccine that could be used effectively against A. pleuropneumoniae infection.",
keywords = "Actinobacillus pleuropneumoniae, Edible vaccine, Transgenic plant",
author = "Lee, {Kyung Yeol} and Kim, {Dong Heon} and Kang, {Tae Jin} and Ju Kim and Chung, {Gook Hyun} and Yoo, {Han Sang} and Arntzen, {Charles J.} and Yang, {Moon Sik} and Jang, {Yong Suk}",
year = "2006",
month = "12",
doi = "10.1111/j.1574-695X.2006.00158.x",
language = "English (US)",
volume = "48",
pages = "381--389",
journal = "Pathogens and Disease",
issn = "2049-632X",
publisher = "John Wiley & Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria

AU - Lee, Kyung Yeol

AU - Kim, Dong Heon

AU - Kang, Tae Jin

AU - Kim, Ju

AU - Chung, Gook Hyun

AU - Yoo, Han Sang

AU - Arntzen, Charles J.

AU - Yang, Moon Sik

AU - Jang, Yong Suk

PY - 2006/12

Y1 - 2006/12

N2 - Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia. Among the virulence factors, ApxIIA, a bacterial exotoxin, is reportedly expressed in many serotypes and is considered as a candidate for the development of a vaccine against the bacterial infection. Previously, we isolated a field strain of A. pleuropneumoniae serotype 2 in Korea and characterized its exotoxins to develop an oral vaccine. In this study, we initially confirmed the immunogenicity of ApxIIA expressed in Escherichia coli. We then developed transgenic tobacco expressing ApxIIA and tested its efficacy to induce a protective immune response against A. pleuropneumoniae infection after oral administration of the plant powder. We observed that protective immune responses were induced in mice after oral administration of the plant powder once a week for 4 weeks. Immunoassays revealed that the levels of antigen-specific immunoglobulin G against ApxIIA increased in mice that were fed a powder made from the transgenic plant, but not in mice fed a powder made from wild-type tobacco. Additionally, mice fed the transgenic plant powder were protected from an injection of a lethal dose of A. pleuropneumoniae. These results support that the transgenic plant may be a suitable candidate for an oral vaccine that could be used effectively against A. pleuropneumoniae infection.

AB - Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia. Among the virulence factors, ApxIIA, a bacterial exotoxin, is reportedly expressed in many serotypes and is considered as a candidate for the development of a vaccine against the bacterial infection. Previously, we isolated a field strain of A. pleuropneumoniae serotype 2 in Korea and characterized its exotoxins to develop an oral vaccine. In this study, we initially confirmed the immunogenicity of ApxIIA expressed in Escherichia coli. We then developed transgenic tobacco expressing ApxIIA and tested its efficacy to induce a protective immune response against A. pleuropneumoniae infection after oral administration of the plant powder. We observed that protective immune responses were induced in mice after oral administration of the plant powder once a week for 4 weeks. Immunoassays revealed that the levels of antigen-specific immunoglobulin G against ApxIIA increased in mice that were fed a powder made from the transgenic plant, but not in mice fed a powder made from wild-type tobacco. Additionally, mice fed the transgenic plant powder were protected from an injection of a lethal dose of A. pleuropneumoniae. These results support that the transgenic plant may be a suitable candidate for an oral vaccine that could be used effectively against A. pleuropneumoniae infection.

KW - Actinobacillus pleuropneumoniae

KW - Edible vaccine

KW - Transgenic plant

UR - http://www.scopus.com/inward/record.url?scp=33750942121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750942121&partnerID=8YFLogxK

U2 - 10.1111/j.1574-695X.2006.00158.x

DO - 10.1111/j.1574-695X.2006.00158.x

M3 - Article

VL - 48

SP - 381

EP - 389

JO - Pathogens and Disease

JF - Pathogens and Disease

SN - 2049-632X

IS - 3

ER -